The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment
Background Patient-reported outcome measures (PROMs) are used in health technology assessment (HTA) to measure patient experiences with disease and treatment, allowing a deeper understanding of treatment impact beyond clinical endpoints. Developing and administering PROMs for rare diseases poses uni...
Uloženo v:
| Vydáno v: | The patient : patient-centered outcomes research Ročník 14; číslo 5; s. 485 - 503 |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Cham
Springer International Publishing
01.09.2021
Springer Nature B.V |
| Témata: | |
| ISSN: | 1178-1653, 1178-1661, 1178-1661 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background
Patient-reported outcome measures (PROMs) are used in health technology assessment (HTA) to measure patient experiences with disease and treatment, allowing a deeper understanding of treatment impact beyond clinical endpoints. Developing and administering PROMs for rare diseases poses unique challenges because of small patient populations, disease heterogeneity, lack of natural history knowledge, and short-term studies.
Objective
This research aims to identify key factors to consider when using different types of PROMs in HTA for rare disease treatments (RDTs).
Methods
A scoping review of scientific and grey literature was conducted, with no date or publication type restrictions. Information on the advantages of and the challenges and potential solutions when using different types of PROMs for RDTs, including psychometric properties, was extracted and synthesized.
Results
Of 79 records from PubMed, 32 were included, plus 12 records from the grey literature. PROMs for rare diseases face potential data collection and psychometric challenges resulting from small patient populations and disease heterogeneity. Generic PROMs are comparable across diseases but not sensitive to disease specificities. Disease-specific instruments are sensitive but do not exist for many rare diseases and rarely provide the utility values required by some HTA bodies. Creating new PROMs is time and resource intensive. Potential solutions include pooling data (multi-site/international data collection), using computer-assisted technology, or using generic and disease-specific PROMs in a complementary way.
Conclusions
PROMs are relevant in HTA for RDTs but pose a number of difficulties. A deeper understanding of the potential advantages of and the challenges and potential solutions for each can help manage these difficulties. |
|---|---|
| AbstractList | Background Patient-reported outcome measures (PROMs) are used in health technology assessment (HTA) to measure patient experiences with disease and treatment, allowing a deeper understanding of treatment impact beyond clinical endpoints. Developing and administering PROMs for rare diseases poses unique challenges because of small patient populations, disease heterogeneity, lack of natural history knowledge, and short-term studies. Objective This research aims to identify key factors to consider when using different types of PROMs in HTA for rare disease treatments (RDTs). Methods A scoping review of scientific and grey literature was conducted, with no date or publication type restrictions. Information on the advantages of and the challenges and potential solutions when using different types of PROMs for RDTs, including psychometric properties, was extracted and synthesized. Results Of 79 records from PubMed, 32 were included, plus 12 records from the grey literature. PROMs for rare diseases face potential data collection and psychometric challenges resulting from small patient populations and disease heterogeneity. Generic PROMs are comparable across diseases but not sensitive to disease specificities. Disease-specific instruments are sensitive but do not exist for many rare diseases and rarely provide the utility values required by some HTA bodies. Creating new PROMs is time and resource intensive. Potential solutions include pooling data (multi-site/international data collection), using computer-assisted technology, or using generic and disease-specific PROMs in a complementary way. Conclusions PROMs are relevant in HTA for RDTs but pose a number of difficulties. A deeper understanding of the potential advantages of and the challenges and potential solutions for each can help manage these difficulties. Patient-reported outcome measures (PROMs) are used in health technology assessment (HTA) to measure patient experiences with disease and treatment, allowing a deeper understanding of treatment impact beyond clinical endpoints. Developing and administering PROMs for rare diseases poses unique challenges because of small patient populations, disease heterogeneity, lack of natural history knowledge, and short-term studies. This research aims to identify key factors to consider when using different types of PROMs in HTA for rare disease treatments (RDTs). A scoping review of scientific and grey literature was conducted, with no date or publication type restrictions. Information on the advantages of and the challenges and potential solutions when using different types of PROMs for RDTs, including psychometric properties, was extracted and synthesized. Of 79 records from PubMed, 32 were included, plus 12 records from the grey literature. PROMs for rare diseases face potential data collection and psychometric challenges resulting from small patient populations and disease heterogeneity. Generic PROMs are comparable across diseases but not sensitive to disease specificities. Disease-specific instruments are sensitive but do not exist for many rare diseases and rarely provide the utility values required by some HTA bodies. Creating new PROMs is time and resource intensive. Potential solutions include pooling data (multi-site/international data collection), using computer-assisted technology, or using generic and disease-specific PROMs in a complementary way. PROMs are relevant in HTA for RDTs but pose a number of difficulties. A deeper understanding of the potential advantages of and the challenges and potential solutions for each can help manage these difficulties. Background Patient-reported outcome measures (PROMs) are used in health technology assessment (HTA) to measure patient experiences with disease and treatment, allowing a deeper understanding of treatment impact beyond clinical endpoints. Developing and administering PROMs for rare diseases poses unique challenges because of small patient populations, disease heterogeneity, lack of natural history knowledge, and short-term studies. Objective This research aims to identify key factors to consider when using different types of PROMs in HTA for rare disease treatments (RDTs). Methods A scoping review of scientific and grey literature was conducted, with no date or publication type restrictions. Information on the advantages of and the challenges and potential solutions when using different types of PROMs for RDTs, including psychometric properties, was extracted and synthesized. Results Of 79 records from PubMed, 32 were included, plus 12 records from the grey literature. PROMs for rare diseases face potential data collection and psychometric challenges resulting from small patient populations and disease heterogeneity. Generic PROMs are comparable across diseases but not sensitive to disease specificities. Disease-specific instruments are sensitive but do not exist for many rare diseases and rarely provide the utility values required by some HTA bodies. Creating new PROMs is time and resource intensive. Potential solutions include pooling data (multi-site/international data collection), using computer-assisted technology, or using generic and disease-specific PROMs in a complementary way. Conclusions PROMs are relevant in HTA for RDTs but pose a number of difficulties. A deeper understanding of the potential advantages of and the challenges and potential solutions for each can help manage these difficulties. Patient-reported outcome measures (PROMs) are used in health technology assessment (HTA) to measure patient experiences with disease and treatment, allowing a deeper understanding of treatment impact beyond clinical endpoints. Developing and administering PROMs for rare diseases poses unique challenges because of small patient populations, disease heterogeneity, lack of natural history knowledge, and short-term studies.BACKGROUNDPatient-reported outcome measures (PROMs) are used in health technology assessment (HTA) to measure patient experiences with disease and treatment, allowing a deeper understanding of treatment impact beyond clinical endpoints. Developing and administering PROMs for rare diseases poses unique challenges because of small patient populations, disease heterogeneity, lack of natural history knowledge, and short-term studies.This research aims to identify key factors to consider when using different types of PROMs in HTA for rare disease treatments (RDTs).OBJECTIVEThis research aims to identify key factors to consider when using different types of PROMs in HTA for rare disease treatments (RDTs).A scoping review of scientific and grey literature was conducted, with no date or publication type restrictions. Information on the advantages of and the challenges and potential solutions when using different types of PROMs for RDTs, including psychometric properties, was extracted and synthesized.METHODSA scoping review of scientific and grey literature was conducted, with no date or publication type restrictions. Information on the advantages of and the challenges and potential solutions when using different types of PROMs for RDTs, including psychometric properties, was extracted and synthesized.Of 79 records from PubMed, 32 were included, plus 12 records from the grey literature. PROMs for rare diseases face potential data collection and psychometric challenges resulting from small patient populations and disease heterogeneity. Generic PROMs are comparable across diseases but not sensitive to disease specificities. Disease-specific instruments are sensitive but do not exist for many rare diseases and rarely provide the utility values required by some HTA bodies. Creating new PROMs is time and resource intensive. Potential solutions include pooling data (multi-site/international data collection), using computer-assisted technology, or using generic and disease-specific PROMs in a complementary way.RESULTSOf 79 records from PubMed, 32 were included, plus 12 records from the grey literature. PROMs for rare diseases face potential data collection and psychometric challenges resulting from small patient populations and disease heterogeneity. Generic PROMs are comparable across diseases but not sensitive to disease specificities. Disease-specific instruments are sensitive but do not exist for many rare diseases and rarely provide the utility values required by some HTA bodies. Creating new PROMs is time and resource intensive. Potential solutions include pooling data (multi-site/international data collection), using computer-assisted technology, or using generic and disease-specific PROMs in a complementary way.PROMs are relevant in HTA for RDTs but pose a number of difficulties. A deeper understanding of the potential advantages of and the challenges and potential solutions for each can help manage these difficulties.CONCLUSIONSPROMs are relevant in HTA for RDTs but pose a number of difficulties. A deeper understanding of the potential advantages of and the challenges and potential solutions for each can help manage these difficulties. |
| Author | Meregaglia, Michela Whittal, Amanda Nicod, Elena |
| Author_xml | – sequence: 1 givenname: Amanda orcidid: 0000-0003-2908-9005 surname: Whittal fullname: Whittal, Amanda email: amanda.whittal@unibocconi.it organization: Centre for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management – sequence: 2 givenname: Michela orcidid: 0000-0003-0092-5970 surname: Meregaglia fullname: Meregaglia, Michela organization: Centre for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management – sequence: 3 givenname: Elena orcidid: 0000-0001-6798-9923 surname: Nicod fullname: Nicod, Elena organization: Centre for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33462774$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UU1P3DAQtSqqAtv-gR4qS730ktZfsZNLJUQ_QKKiQsvZMs5k1yixt3YC4t93YOm25YAvtmbee_PG75DsxRSBkLecfeSMmU9FMWF4xQSrGFOtrG5fkAPOTVNxrfne7l3LfXJYyjVjGhv6FdmXUmlhjDogabkGelmApp7-dFOAOFUXsEl5go6ez5NPI9Af4MqcodAQ6YXLQL-EgiUsuNjR03EzBI_cFAvtU6Yn4IZpTZfg1zENaXVHjwqCy4jir8nL3g0F3jzeC3L57evy-KQ6O_9-enx0Vnll1FSpxnmGR1ypuqu5kK0WTeM1aO20Np0D3koles77lmnjXAeNhxYRvcavkXJBPm91N_PVCJ3H0dkNdpPD6PKdTS7Y_zsxrO0q3dhG1sagwoJ8eBTI6dcMZbJjKB6GwUVIc7FCmZYp9HAPff8Eep3mHHE9K2rN2wZ_ukXUu38d7az8yQIBYgvwOZWSod9BOLP3gdtt4BYDtw-B21skNU9IPkwPWeBWYXieKrfUgnPiCvJf28-wfgML2MBx |
| CitedBy_id | crossref_primary_10_1080_14737167_2023_2193690 crossref_primary_10_1177_19458924231207123 crossref_primary_10_1093_jsxmed_qdaf018 crossref_primary_10_1186_s13023_024_03382_9 crossref_primary_10_1080_14737167_2024_2360201 crossref_primary_10_1111_jep_70010 crossref_primary_10_3233_JND_240003 crossref_primary_10_1016_j_jval_2022_04_1724 crossref_primary_10_1007_s40273_021_01050_5 crossref_primary_10_1007_s40273_023_01262_x crossref_primary_10_1007_s10198_023_01667_7 crossref_primary_10_1371_journal_pone_0298796 crossref_primary_10_1007_s10198_021_01387_w crossref_primary_10_3390_jpm12111811 crossref_primary_10_1080_13696998_2025_2522010 crossref_primary_10_1007_s10198_024_01748_1 crossref_primary_10_1016_j_jval_2025_02_018 crossref_primary_10_1136_rmdopen_2021_001783 crossref_primary_10_3390_jmahp13030037 crossref_primary_10_7759_cureus_70468 crossref_primary_10_1371_journal_pone_0332388 crossref_primary_10_3389_fimmu_2024_1430678 crossref_primary_10_3390_genes13071104 crossref_primary_10_1016_j_jval_2025_05_002 crossref_primary_10_1007_s10198_022_01541_y crossref_primary_10_1177_1759720X251369963 crossref_primary_10_3390_biomedicines13081796 crossref_primary_10_1177_24730114231213369 crossref_primary_10_1007_s00467_025_06912_0 crossref_primary_10_3389_fneur_2025_1481825 crossref_primary_10_1016_j_jclinepi_2024_111617 crossref_primary_10_1007_s11136_025_03937_8 crossref_primary_10_1007_s40271_022_00583_x crossref_primary_10_5662_wjm_v15_i2_98066 crossref_primary_10_1007_s00277_021_04715_5 crossref_primary_10_1212_WNL_0000000000209549 crossref_primary_10_14309_ctg_0000000000000709 crossref_primary_10_1093_bjsopen_zrad098 crossref_primary_10_1111_aos_15794 crossref_primary_10_1016_j_bone_2022_116635 crossref_primary_10_1016_j_ejmg_2024_104974 crossref_primary_10_1016_j_heliyon_2024_e36645 crossref_primary_10_1177_27325016241310907 crossref_primary_10_1371_journal_pone_0301452 crossref_primary_10_1016_j_jaad_2025_03_022 crossref_primary_10_2340_jphs_v59_19649 crossref_primary_10_1186_s12955_023_02216_9 crossref_primary_10_1186_s12913_023_10049_x crossref_primary_10_1007_s10803_024_06238_0 crossref_primary_10_1007_s40271_022_00598_4 crossref_primary_10_1016_j_hpb_2024_04_004 crossref_primary_10_1186_s13023_025_03742_z crossref_primary_10_1007_s40273_025_01538_4 crossref_primary_10_1186_s13023_021_02169_6 crossref_primary_10_1093_jbmrpl_ziae062 |
| Cites_doi | 10.1007/s40273-020-00897-4 10.1007/s12325-019-00920-x 10.1097/01.mlr.0000258615.42478.55 10.1007/s40273-017-0545-x 10.1186/s13023-017-0718-x 10.1111/jns5.12059 10.1016/j.jval.2017.05.017 10.1186/1477-7525-8-77 10.1007/s11606-014-2892-z 10.1016/j.jval.2019.03.010 10.1002/cncr.32555 10.1007/s40271-019-00400-y 10.1017/S0266462316000568 10.1111/dmcn.13277 10.1007/s11136-018-2025-y 10.1111/dmcn.13977 10.1023/A:1008846618880 10.1186/s12931-019-1010-5 10.1186/s13023-019-1254-7 10.1513/AnnalsATS.201603-198OC 10.1016/j.vhri.2014.06.003 10.2147/PPA.S201632 10.1186/s40900-018-0093-3 10.1186/s13023-019-1004-x 10.1186/s13023-019-1108-3 10.1016/j.ejca.2007.05.029 10.1007/s00198-018-4690-7 10.1186/s41687-019-0099-0 10.1016/j.ekir.2017.11.016 10.1016/j.jval.2017.05.015 10.1111/j.1524-4733.2005.04054.x 10.1186/s13023-018-0810-x 10.1186/s13023-018-0958-4 10.1186/s13023-020-01400-0 10.1016/j.jclinepi.2016.06.010 10.1038/s41431-019-0508-0 10.1186/s13023-016-0444-9 10.7326/M18-0850 10.1017/S0266462316000271 10.1007/s40273-017-0546-9 10.1007/s11136-011-9960-1 10.1186/s13023-016-0528-6 10.1186/s12874-015-0071-5 10.1002/ppul.24507 10.1186/s41687-019-0123-4 10.1186/s13023-018-0953-9 10.1208/s12248-013-9452-z |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021 2021. The Author(s). Copyright Springer Nature B.V. Sep 2021 |
| Copyright_xml | – notice: The Author(s) 2021 – notice: 2021. The Author(s). – notice: Copyright Springer Nature B.V. Sep 2021 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 4T- 7RV 7X7 7XB 88E 8C1 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU FYUFA GHDGH K9- K9. KB0 M0R M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1007/s40271-020-00493-w |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Docstoc Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Local Electronic Collection Information ProQuest Central ProQuest One Health Research Premium Collection Health Research Premium Collection (Alumni) Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Consumer Health Database ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Family Health (Alumni Edition) ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Docstoc ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Academic Middle East (New) MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & allied health premium. url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1178-1661 |
| EndPage | 503 |
| ExternalDocumentID | PMC8357707 33462774 10_1007_s40271_020_00493_w |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GrantInformation_xml | – fundername: Horizon 2020 Framework Programme grantid: 779312 funderid: http://dx.doi.org/10.13039/100010661 – fundername: ; grantid: 779312 |
| GroupedDBID | --- -EM 04C 0R~ 29O 3V. 4.4 406 53G 7RV 7X7 88E 8C1 8FI 8FJ 8R4 8R5 8UJ 95. AACDK AADNT AAIKX AAJKR AAKAS AASML AATNV ABAKF ABDZT ABFTV ABIVO ABJOX ABKCH ABKTR ABLLE ABPLI ABTKH ABTMW ABUWG ABXPI ACAOD ACCOQ ACDTI ACGFS ACMLO ACPIV ACZOJ ADBBV ADFZG ADURQ ADZCM ADZKW AEFQL AEJHL AEJRE AEMSY AEOHA AESKC AFKRA AFZKB AGDGC AGQEE AGQMX AHMBA AHSBF AIGIU AILAN ALMA_UNASSIGNED_HOLDINGS AMKLP AMXSW ASPBG AUKKA AVWKF AWSVR AXYYD AZQEC BENPR BGNMA BKEYQ BKNYI BMSDO BPHCQ BVXVI BYPQX C6C CAG CCPQU COF DCUDU DPUIP EBS EIHBH EJD EMOBN EX3 F5P FIGPU FLLZZ FNLPD FSGXE FYUFA HMCUK IAO IEA IHR ITC IWAJR J-C JZLTJ K9- LLZTM M0R M1P M4Y NAPCQ NQJWS NU0 O9- OAC OVD PQQKQ PROAC PSQYO Q2X ROL RSV SISQX SJYHP SNPRN SOHCF SOJ SPKJE SRMVM SSLCW SV3 TEORI TSG U9L UG4 UKHRP UTJUX VDBLX VFIZW W48 WOW ~JE AAYXX ABBRH ABDBE ABRTQ AFDZB AFFHD ATHPR AYFIA CITATION EBLON PHGZM PHGZT PJZUB PPXIY CGR CUY CVF ECM EIF NPM 4T- 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c474t-48ac00002b45d512396288c6e66a667dae19342f11f9067aade8ce98c6f600733 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 65 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000608643800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1178-1653 1178-1661 |
| IngestDate | Tue Nov 04 01:47:33 EST 2025 Thu Oct 02 10:49:26 EDT 2025 Fri Nov 07 23:30:40 EST 2025 Wed Feb 19 02:27:12 EST 2025 Sat Nov 29 02:34:22 EST 2025 Tue Nov 18 22:28:56 EST 2025 Fri Feb 21 02:47:44 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | 2021. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c474t-48ac00002b45d512396288c6e66a667dae19342f11f9067aade8ce98c6f600733 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0001-6798-9923 0000-0003-2908-9005 0000-0003-0092-5970 |
| OpenAccessLink | https://link.springer.com/10.1007/s40271-020-00493-w |
| PMID | 33462774 |
| PQID | 2561987749 |
| PQPubID | 38894 |
| PageCount | 19 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8357707 proquest_miscellaneous_2479043427 proquest_journals_2561987749 pubmed_primary_33462774 crossref_primary_10_1007_s40271_020_00493_w crossref_citationtrail_10_1007_s40271_020_00493_w springer_journals_10_1007_s40271_020_00493_w |
| PublicationCentury | 2000 |
| PublicationDate | 2021-09-01 |
| PublicationDateYYYYMMDD | 2021-09-01 |
| PublicationDate_xml | – month: 09 year: 2021 text: 2021-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Cham |
| PublicationPlace_xml | – name: Cham – name: New Zealand – name: Auckland |
| PublicationSubtitle | An Official Journal of the International Academy of Health Preference Research |
| PublicationTitle | The patient : patient-centered outcomes research |
| PublicationTitleAbbrev | Patient |
| PublicationTitleAlternate | Patient |
| PublicationYear | 2021 |
| Publisher | Springer International Publishing Springer Nature B.V |
| Publisher_xml | – name: Springer International Publishing – name: Springer Nature B.V |
| References | SladeAPatient reported outcome measures in rare diseases: A narrative reviewOrphanet J Rare Dis201810.1186/s13023-018-0810-x296888605914068 TosiLLAssessing disease experience across the life span for individuals with osteogenesis imperfecta: Challenges and opportunities for patient-reported outcomes (PROs) measurement: A pilot studyOrphanet J Rare Dis201910.1186/s13023-019-1004-x306964676350324 RowenDBrazierJAraRAzzabiIRowenDThe role of condition-specific preference-based measures in health technology assessmentPharmacoeconomics201735s1334110.1007/s40273-017-0546-929052164 MeregagliaMWhittalANicodEDrummondMMapping’ health state utility values from non-preference-based measures: a systematic literature review in rare diseasesPharmacoeconomics202010.1007/s40273-020-00897-432152892 WhittyJAPatient preferences in the medical product lifecyclePatient202013171010.1007/s40271-019-00400-y31782120 WildDPrinciples of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: Report of the ISPOR Task Force for Translation and Cultural AdaptationValue Health2005829410410.1111/j.1524-4733.2005.04054.x15804318 MorelTAyméSCassimanDSimoensSMorganMVandebroekMQuantifying benefit-risk preferences for new medicines in rare disease patients and caregiversOrphanet J Rare Dis201611111210.1186/s13023-016-0444-9 LanarSAcquadroCSeatonJSavreIArnouldBTo what degree are orphan drugs patient-centered? A review of the current state of clinical research in rare diseasesOrphanet J Rare Dis.20201511810.1186/s13023-020-01400-0 PascoalCPatient and observer reported outcome measures to evaluate health-related quality of life in inherited metabolic diseases: A SCOPING reviewOrphanet J Rare Dis201810.1186/s13023-018-0953-9304868336263554 GounderMMMadduxLAPatyJAtkinsonTMProspective development of a patient-reported outcomes instrument for desmoid tumors or aggressive fibromatosisCancer2020126353153910.1002/cncr.3255531691276 Mapi Research Trust. ePROVIDE Online Support in Clinical Outcome Assessments. https://eprovide.mapi-trust.org/search?form[searchText]=&form[ezxform_token]=vm5mY6mwXBfdtdI8lIZbV5vT3P8YndbDBnIiXAa3gLI. Accessed 20 Nov 2019. Davio K. Patient-reported outcome measures are key to understanding rare disease. Am J Managed Care, [Internet]. 2018, https://www.ajmc.com/view/patientreported-outcome-measures-are-key-to-understanding-rare-diseases Accessed 11 Nov 2019. BaschEBennettAVPatient-reported outcomes in clinical trials of rare diseasesJ Gen Intern Med201429SUPPL. 380180310.1007/s11606-014-2892-z4124120 ChalasaniMVaidyaPMullinTEnhancing the incorporation of the patient’s voice in drug development and evaluationRes Invol Engag201841010.1186/s40900-018-0093-3 NoëlETreatment needs and expectations for Fabry disease in France: Development of a new Patient Needs QuestionnaireOrphanet J Rare Dis201914111010.1186/s13023-019-1254-7 Teynor M, et al. Benchmarking utility estimates in rare diseases may guide the selection of data inputs in health economic modelling. In: 2018, European Conference on Rare Diseases and Orphan Products. SmithAWhat are PROMsYork Health Econ Consort.20144412 SkoupáJAnnemansLHájekPHealth economic data requirements and availability in the European Union: results of a survey among 10 European countriesValue Health Reg issues20144535710.1016/j.vhri.2014.06.003 U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. In: Patient-focused drug development: collecting comprehensive and representative input. Silver Spring, MD; 2018. GipsonDSNephCure accelerating cures institute: a multidisciplinary consortium to improve care for nephrotic syndromeKidney Int Rep20183243944610.1016/j.ekir.2017.11.01629725648 BaiJPBarrettJSBurckartGJMeibohmBSachsHCYaoLStrategic biomarkers for drug development in treating rare diseases and diseases in neonates and infantsAAPS J20131524474541:CAS:528:DC%2BC3sXlsF2htrw%3D10.1208/s12248-013-9452-z CellaDYountSRothrockNGershonRCookKReeveBAderDFriesJFBruceBRoseMThe patient-reported outcomes measurement information system (PROMIS): progress of an NIH roadmap cooperative group during its first two yearsMed Care.200745S3S1110.1097/01.mlr.0000258615.42478.55 KnobleNNayrolesGChengCArnouldBIllustration of patient-reported outcome challenges and solutions in rare diseases: A systematic review in Cushing’s syndromeOrphanet J Rare Dis201810.1186/s13023-018-0958-4305675826299940 Sampson C, Garau M. How should we measure quality of life impact in rare disease? recent learnings in spinal muscular atrophy. 2019, Office of Health Economics, no. 002146. BehanLLeighMWDellSDQuittnerALHoggCLucasJSValidation of pediatric health-related quality of life instruments for primary ciliary dyskinesia (QOL-PCD)Pediatr Pulmonol201954122011202010.1002/ppul.24507314754796851410 DellSDPrimary ciliary dyskinesia: First health-related quality-of-life measures for pediatric patientsAnn Am Thorac Soc201613101726173510.1513/AnnalsATS.201603-198OC274643045122491 MillerPAMullaSMAdams-WebberTSivjiYGuyattGHJohnstonBCPatient-reported outcomes in rare lysosomal storage diseases: key informant interviews and a systematic review protocolInt J Technol Assess Health Care201632639339910.1017/S026646231600056828029334 GarrardLPriceLRBottMJGajewskiBJA novel method for expediting the development of patient-reported outcome measures and an evaluation of its performance via simulationBMC Med Res Methodol201515111410.1186/s12874-015-0071-5 WittSPsychometric properties and minimal important differences of SF-36 in Idiopathic Pulmonary FibrosisRespir Res201920111110.1186/s12931-019-1010-5 JavaidMKThe RUDY study platform - a novel approach to patient driven research in rare musculoskeletal diseasesOrphanet J Rare Dis20161111910.1186/s13023-016-0528-6 SoleboALBarryRJKeanePARahiJSDennistonAKUnder-utilisation of reproducible, child appropriate or patient reported outcome measures in childhood uveitis interventional researchOrphanet J. Rare Dis.201914111110.1186/s13023-019-1108-3 Sabino G, Mills A, Jonker AH, et al. Patient-Centered Outcome Measures in the Field of Rare Diseases: International Rare Diseases Research Consortium (IRDiRC), 2016. http://www.irdirc.org/wp-content/uploads/2016/03/PCOM_Post-Workshop_Report_Final.pdf. Accessed 5 Nov 2019. AcasterSPatient-reported outcome and observer-reported outcome assessment in rare disease trialsValue Heal.201720785685710.1016/j.jval.2017.05.017 HerdmanMFox-RushbyJBadiaXA model of equivalence in the cultural adaptation of HRQoLinstruments: the universalist approachQual Life Res199873233351:STN:280:DyaK1c3ntlWgtA%3D%3D10.1023/A:1008846618880 Klingels K, et al. Development of a patient-reported outcome measure for upper limb function in Duchenne muscular dystrophy: DMD Upper Limb PROM. 2016, https://doi.org/10.1111/dmcn.13277. US FDA. Patient-reported outcomes (PROs) in medical device decision-making, [Internet]. 2019, https://www.fda.gov/about-fda/cdrh-patient-engagement/patient-reported-outcomes-pros-medical-device-decision-making#whatare. Accessed 25 June 2019. HongYDVillalonga-OlivesEPerfettoEMPatient-reported outcomes in orphan drug labels approved by the us food and drug administrationValue Health201922892593010.1016/j.jval.2019.03.01031426934 SwigrisJJWilsonSRGreenKESprungerDBBrownKKWamboldtFSDevelopment of the ATAQ-IPF: A tool to assess quality of life in IPFHealth Qual Life Outcomes201081910.1186/1477-7525-8-77 ContesseMGValentineJEWallTELefflerMGThe Case for the use of patient and caregiver perception of change assessments in rare disease clinical trials: a methodologic overviewAdv Ther2019365997101010.1007/s12325-019-00920-x308792506824378 SwezeyTIncorporating the patient perspective in the study of rare bone disease: insights from the osteogenesis imperfecta communityOsteoporos Int201910.1007/s00198-018-4690-730191258 ProppRDevelopment and content validation of the Muscular Dystrophy Child Health Index of Life with Disabilities questionnaire for children with Duchenne muscular dystrophyDev Med Child Neurol2018611758110.1111/dmcn.1397730058069 Devlin N, Lorgelly P, Herdman M. Can We Really Compare and Aggregate PRO Data Between People and Settings? Implications for Multi-Country Clinical Trials and HTA. OHE Res. Pap., no. April, 2019. GelhornHLThe measurement of physical functioning among patients with Tenosynovial Giant Cell Tumor (TGCT) using the Patient-Reported Outcomes Measurement Information System (PROMIS)J. Patient-Rep Outcomes20193111010.1186/s41687-019-0099-0 HollinILDimmockAEFBridgesJFPDanoffSKBascomRCollecting patient preference information using a clinical data research network: demonstrating feasibility with idiopathic pulmonary fibrosisPatient Prefer Adhere20191379580410.2147/PPA.S201632 TriccoACPRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanationAnn Intern Med2018169746747310.7326/M18-085030178033 WakapSNLambertDMOlryARodwellCGueydanCLanneauVMurphyDLe CamYRathAEstimating cumulative point prevalence of rare diseases: analysis of the Orphanet databaseEur J Hum Genet202028216517310.1038/s41431-019-0508-0 BrazierJAraRRowenDChevrou-SeveracHA review of generic preference-based measures for use in cost-effectiveness modelsPharmacoeconomics201735s1213110.1007/s40273-017-0545-x29052157 RütherAElsteinDWong-RiegerDGuyattGAspects of patient reported outcomes in rare diseases: A discussion paperInt J Technol Assess Health Care201632312613010.1017/S026646231600027127523091 TerweeCBMokkinkLBKnolDLOsteloRWBouterLMde VetHCRating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklistQual Life Res201221465165710.1007/s11136-011-9960-1 IQVIA. “PROving is worth: how to develop a PRO strategy to distinguish your product with regulators and payers webinar (Europe),” [Internet]. 2018, https://www.iqvia.com/events/2018/09/proving-its-worth-how-to-develop-a-pro-strategy-to-distinguish-your-product Accessed 18 493_CR34 T Morel (493_CR56) 2016; 11 493_CR33 MK Javaid (493_CR26) 2016; 11 JP Bai (493_CR8) 2013; 15 CB Terwee (493_CR40) 2012; 21 M Meregaglia (493_CR50) 2020 PA Miller (493_CR9) 2016; 32 M Chalasani (493_CR44) 2018; 4 K Benjamin (493_CR13) 2017 493_CR41 R Propp (493_CR58) 2018; 61 493_CR43 493_CR22 S Witt (493_CR37) 2019; 20 493_CR28 MG Contesse (493_CR7) 2019; 36 493_CR1 E Noël (493_CR35) 2019; 14 S Acaster (493_CR12) 2017; 20 493_CR5 M Herdman (493_CR27) 1998; 7 A Rüther (493_CR31) 2016; 32 DS Gipson (493_CR55) 2018; 3 EJ Vinik (493_CR39) 2014; 19 JA Whitty (493_CR6) 2020; 13 LL Tosi (493_CR17) 2019 L Behan (493_CR48) 2019; 54 JJ Swigris (493_CR59) 2010; 8 SD Dell (493_CR57) 2016; 13 T Swezey (493_CR19) 2019 IL Hollin (493_CR25) 2019; 13 E Basch (493_CR23) 2014; 29 AL Solebo (493_CR49) 2019; 14 JA Bell (493_CR3) 2019 HL Gelhorn (493_CR38) 2019; 3 T Morel (493_CR16) 2017 SN Wakap (493_CR52) 2020; 28 MM Gounder (493_CR54) 2020; 126 C Pascoal (493_CR14) 2018 M Koller (493_CR29) 2007; 43 AC Tricco (493_CR20) 2018; 169 A Smith (493_CR2) 2014; 44 493_CR21 493_CR45 493_CR46 A Slade (493_CR15) 2018 YD Hong (493_CR32) 2019; 22 S Lanar (493_CR60) 2020; 15 MS Salek (493_CR47) 2019; 28 L Garrard (493_CR24) 2015; 15 N Knoble (493_CR18) 2018 D Rowen (493_CR51) 2017; 35 D Cella (493_CR42) 2007; 45 J Brazier (493_CR4) 2017; 35 493_CR10 D Wild (493_CR30) 2005; 8 BC Johnston (493_CR36) 2016; 79 J Skoupá (493_CR11) 2014; 4 493_CR53 |
| References_xml | – reference: HongYDVillalonga-OlivesEPerfettoEMPatient-reported outcomes in orphan drug labels approved by the us food and drug administrationValue Health201922892593010.1016/j.jval.2019.03.01031426934 – reference: TerweeCBMokkinkLBKnolDLOsteloRWBouterLMde VetHCRating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklistQual Life Res201221465165710.1007/s11136-011-9960-1 – reference: BellJAA pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemiaJ Patient-Rep Outcomes201910.1186/s41687-019-0123-4312184546584583 – reference: MorelTCanoSJMeasuring what matters to rare disease patients - Reflections on the work by the IRDiRC taskforce on patient-centered outcome measuresOrphanet J Rare Dis201710.1186/s13023-017-0718-x290966635667521 – reference: BaschEBennettAVPatient-reported outcomes in clinical trials of rare diseasesJ Gen Intern Med201429SUPPL. 380180310.1007/s11606-014-2892-z4124120 – reference: GipsonDSNephCure accelerating cures institute: a multidisciplinary consortium to improve care for nephrotic syndromeKidney Int Rep20183243944610.1016/j.ekir.2017.11.01629725648 – reference: WittSPsychometric properties and minimal important differences of SF-36 in Idiopathic Pulmonary FibrosisRespir Res201920111110.1186/s12931-019-1010-5 – reference: CellaDYountSRothrockNGershonRCookKReeveBAderDFriesJFBruceBRoseMThe patient-reported outcomes measurement information system (PROMIS): progress of an NIH roadmap cooperative group during its first two yearsMed Care.200745S3S1110.1097/01.mlr.0000258615.42478.55 – reference: KollerMTranslation procedures for standardised quality of life questionnaires: The European Organisation for Research and Treatment of Cancer (EORTC) approachEur J Cancer200743121810182010.1016/j.ejca.2007.05.02917689070 – reference: JavaidMKThe RUDY study platform - a novel approach to patient driven research in rare musculoskeletal diseasesOrphanet J Rare Dis20161111910.1186/s13023-016-0528-6 – reference: RowenDBrazierJAraRAzzabiIRowenDThe role of condition-specific preference-based measures in health technology assessmentPharmacoeconomics201735s1334110.1007/s40273-017-0546-929052164 – reference: Davio K. Patient-reported outcome measures are key to understanding rare disease. Am J Managed Care, [Internet]. 2018, https://www.ajmc.com/view/patientreported-outcome-measures-are-key-to-understanding-rare-diseases Accessed 11 Nov 2019. – reference: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. In: Patient-focused drug development: collecting comprehensive and representative input. Silver Spring, MD; 2018. – reference: SkoupáJAnnemansLHájekPHealth economic data requirements and availability in the European Union: results of a survey among 10 European countriesValue Health Reg issues20144535710.1016/j.vhri.2014.06.003 – reference: WhittyJAPatient preferences in the medical product lifecyclePatient202013171010.1007/s40271-019-00400-y31782120 – reference: AcasterSPatient-reported outcome and observer-reported outcome assessment in rare disease trialsValue Heal.201720785685710.1016/j.jval.2017.05.017 – reference: GarrardLPriceLRBottMJGajewskiBJA novel method for expediting the development of patient-reported outcome measures and an evaluation of its performance via simulationBMC Med Res Methodol201515111410.1186/s12874-015-0071-5 – reference: NoëlETreatment needs and expectations for Fabry disease in France: Development of a new Patient Needs QuestionnaireOrphanet J Rare Dis201914111010.1186/s13023-019-1254-7 – reference: JohnstonBCLimited responsiveness related to the minimal important difference of patient-reported outcomes in rare diseasesJ Clin Epidemiol201679102110.1016/j.jclinepi.2016.06.01027381737 – reference: ContesseMGValentineJEWallTELefflerMGThe Case for the use of patient and caregiver perception of change assessments in rare disease clinical trials: a methodologic overviewAdv Ther2019365997101010.1007/s12325-019-00920-x308792506824378 – reference: PascoalCPatient and observer reported outcome measures to evaluate health-related quality of life in inherited metabolic diseases: A SCOPING reviewOrphanet J Rare Dis201810.1186/s13023-018-0953-9304868336263554 – reference: Mapi Research Trust. ePROVIDE Online Support in Clinical Outcome Assessments. https://eprovide.mapi-trust.org/search?form[searchText]=&form[ezxform_token]=vm5mY6mwXBfdtdI8lIZbV5vT3P8YndbDBnIiXAa3gLI. Accessed 20 Nov 2019. – reference: ProppRDevelopment and content validation of the Muscular Dystrophy Child Health Index of Life with Disabilities questionnaire for children with Duchenne muscular dystrophyDev Med Child Neurol2018611758110.1111/dmcn.1397730058069 – reference: TriccoACPRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanationAnn Intern Med2018169746747310.7326/M18-085030178033 – reference: IQVIA. “PROving is worth: how to develop a PRO strategy to distinguish your product with regulators and payers webinar (Europe),” [Internet]. 2018, https://www.iqvia.com/events/2018/09/proving-its-worth-how-to-develop-a-pro-strategy-to-distinguish-your-product Accessed 18 Sep 2018. – reference: SalekMSIonovaTJohnsJROlivaENAppraisal of patient-reported outcome measures in analogous diseases and recommendations for use in phase II and III clinical trials of pyruvate kinase deficiencyQual Life Res20192823994101:STN:280:DC%2BB3crivVemsA%3D%3D10.1007/s11136-018-2025-y30456713 – reference: SwigrisJJWilsonSRGreenKESprungerDBBrownKKWamboldtFSDevelopment of the ATAQ-IPF: A tool to assess quality of life in IPFHealth Qual Life Outcomes201081910.1186/1477-7525-8-77 – reference: BrazierJAraRRowenDChevrou-SeveracHA review of generic preference-based measures for use in cost-effectiveness modelsPharmacoeconomics201735s1213110.1007/s40273-017-0545-x29052157 – reference: FDA. Patient-focused drug development guidance public workshop: methods to identify what is important to patients and select, develop or modify fit-for-purpose clinical outcomes assessments [Internet]. 2018. https://www.fda.gov/downloads/Drugs/NewsEvents/UCM620707.pdf. Accessed 25 Sep 2018. – reference: SoleboALBarryRJKeanePARahiJSDennistonAKUnder-utilisation of reproducible, child appropriate or patient reported outcome measures in childhood uveitis interventional researchOrphanet J. Rare Dis.201914111110.1186/s13023-019-1108-3 – reference: Sabino G, Mills A, Jonker AH, et al. Patient-Centered Outcome Measures in the Field of Rare Diseases: International Rare Diseases Research Consortium (IRDiRC), 2016. http://www.irdirc.org/wp-content/uploads/2016/03/PCOM_Post-Workshop_Report_Final.pdf. Accessed 5 Nov 2019. – reference: VinikEJNorfolk QOL-DN: Validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathyJ Peripher Nerv Syst201419210411410.1111/jns5.1205924738700 – reference: US FDA. Patient-reported outcomes (PROs) in medical device decision-making, [Internet]. 2019, https://www.fda.gov/about-fda/cdrh-patient-engagement/patient-reported-outcomes-pros-medical-device-decision-making#whatare. Accessed 25 June 2019. – reference: Teynor M, et al. Benchmarking utility estimates in rare diseases may guide the selection of data inputs in health economic modelling. In: 2018, European Conference on Rare Diseases and Orphan Products. – reference: Report O. Patient-Centred Outcome Measures in Research & Healthcare October 2018, no. October, pp. 1–14, 2018 – reference: MorelTAyméSCassimanDSimoensSMorganMVandebroekMQuantifying benefit-risk preferences for new medicines in rare disease patients and caregiversOrphanet J Rare Dis201611111210.1186/s13023-016-0444-9 – reference: HerdmanMFox-RushbyJBadiaXA model of equivalence in the cultural adaptation of HRQoLinstruments: the universalist approachQual Life Res199873233351:STN:280:DyaK1c3ntlWgtA%3D%3D10.1023/A:1008846618880 – reference: BehanLLeighMWDellSDQuittnerALHoggCLucasJSValidation of pediatric health-related quality of life instruments for primary ciliary dyskinesia (QOL-PCD)Pediatr Pulmonol201954122011202010.1002/ppul.24507314754796851410 – reference: DellSDPrimary ciliary dyskinesia: First health-related quality-of-life measures for pediatric patientsAnn Am Thorac Soc201613101726173510.1513/AnnalsATS.201603-198OC274643045122491 – reference: GounderMMMadduxLAPatyJAtkinsonTMProspective development of a patient-reported outcomes instrument for desmoid tumors or aggressive fibromatosisCancer2020126353153910.1002/cncr.3255531691276 – reference: SmithAWhat are PROMsYork Health Econ Consort.20144412 – reference: RütherAElsteinDWong-RiegerDGuyattGAspects of patient reported outcomes in rare diseases: A discussion paperInt J Technol Assess Health Care201632312613010.1017/S026646231600027127523091 – reference: Sampson C, Garau M. How should we measure quality of life impact in rare disease? recent learnings in spinal muscular atrophy. 2019, Office of Health Economics, no. 002146. – reference: KnobleNNayrolesGChengCArnouldBIllustration of patient-reported outcome challenges and solutions in rare diseases: A systematic review in Cushing’s syndromeOrphanet J Rare Dis201810.1186/s13023-018-0958-4305675826299940 – reference: Devlin N, Lorgelly P, Herdman M. Can We Really Compare and Aggregate PRO Data Between People and Settings? Implications for Multi-Country Clinical Trials and HTA. OHE Res. Pap., no. April, 2019. – reference: TosiLLAssessing disease experience across the life span for individuals with osteogenesis imperfecta: Challenges and opportunities for patient-reported outcomes (PROs) measurement: A pilot studyOrphanet J Rare Dis201910.1186/s13023-019-1004-x306964676350324 – reference: WakapSNLambertDMOlryARodwellCGueydanCLanneauVMurphyDLe CamYRathAEstimating cumulative point prevalence of rare diseases: analysis of the Orphanet databaseEur J Hum Genet202028216517310.1038/s41431-019-0508-0 – reference: HollinILDimmockAEFBridgesJFPDanoffSKBascomRCollecting patient preference information using a clinical data research network: demonstrating feasibility with idiopathic pulmonary fibrosisPatient Prefer Adhere20191379580410.2147/PPA.S201632 – reference: Klingels K, et al. Development of a patient-reported outcome measure for upper limb function in Duchenne muscular dystrophy: DMD Upper Limb PROM. 2016, https://doi.org/10.1111/dmcn.13277. – reference: Morel T. How PROs can change classical clinical trials and endpoints ; how relevant regulations and patient involvement can influence PROs. In: 9th Symposium of the Swiss Clinical Trial Organisation, 2019. – reference: MeregagliaMWhittalANicodEDrummondMMapping’ health state utility values from non-preference-based measures: a systematic literature review in rare diseasesPharmacoeconomics202010.1007/s40273-020-00897-432152892 – reference: MillerPAMullaSMAdams-WebberTSivjiYGuyattGHJohnstonBCPatient-reported outcomes in rare lysosomal storage diseases: key informant interviews and a systematic review protocolInt J Technol Assess Health Care201632639339910.1017/S026646231600056828029334 – reference: SladeAPatient reported outcome measures in rare diseases: A narrative reviewOrphanet J Rare Dis201810.1186/s13023-018-0810-x296888605914068 – reference: WildDPrinciples of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: Report of the ISPOR Task Force for Translation and Cultural AdaptationValue Health2005829410410.1111/j.1524-4733.2005.04054.x15804318 – reference: GelhornHLThe measurement of physical functioning among patients with Tenosynovial Giant Cell Tumor (TGCT) using the Patient-Reported Outcomes Measurement Information System (PROMIS)J. Patient-Rep Outcomes20193111010.1186/s41687-019-0099-0 – reference: LanarSAcquadroCSeatonJSavreIArnouldBTo what degree are orphan drugs patient-centered? A review of the current state of clinical research in rare diseasesOrphanet J Rare Dis.20201511810.1186/s13023-020-01400-0 – reference: BaiJPBarrettJSBurckartGJMeibohmBSachsHCYaoLStrategic biomarkers for drug development in treating rare diseases and diseases in neonates and infantsAAPS J20131524474541:CAS:528:DC%2BC3sXlsF2htrw%3D10.1208/s12248-013-9452-z – reference: BenjaminKVernonMKPatrickDLPerfettoENestler-ParrSBurkeLPatient-reported outcome and observer-reported outcome assessment in rare disease clinical trials: an ISPOR COA Emerging Good Practices Task Force ReportValue Health.201710.1016/j.jval.2017.05.01528712612 – reference: SwezeyTIncorporating the patient perspective in the study of rare bone disease: insights from the osteogenesis imperfecta communityOsteoporos Int201910.1007/s00198-018-4690-730191258 – reference: ChalasaniMVaidyaPMullinTEnhancing the incorporation of the patient’s voice in drug development and evaluationRes Invol Engag201841010.1186/s40900-018-0093-3 – year: 2020 ident: 493_CR50 publication-title: Pharmacoeconomics doi: 10.1007/s40273-020-00897-4 – volume: 36 start-page: 997 issue: 5 year: 2019 ident: 493_CR7 publication-title: Adv Ther doi: 10.1007/s12325-019-00920-x – volume: 45 start-page: S3 year: 2007 ident: 493_CR42 publication-title: Med Care. doi: 10.1097/01.mlr.0000258615.42478.55 – volume: 35 start-page: 21 issue: s1 year: 2017 ident: 493_CR4 publication-title: Pharmacoeconomics doi: 10.1007/s40273-017-0545-x – year: 2017 ident: 493_CR16 publication-title: Orphanet J Rare Dis doi: 10.1186/s13023-017-0718-x – volume: 19 start-page: 104 issue: 2 year: 2014 ident: 493_CR39 publication-title: J Peripher Nerv Syst doi: 10.1111/jns5.12059 – volume: 20 start-page: 856 issue: 7 year: 2017 ident: 493_CR12 publication-title: Value Heal. doi: 10.1016/j.jval.2017.05.017 – volume: 8 start-page: 1 year: 2010 ident: 493_CR59 publication-title: Health Qual Life Outcomes doi: 10.1186/1477-7525-8-77 – ident: 493_CR43 – volume: 29 start-page: 801 issue: SUPPL. 3 year: 2014 ident: 493_CR23 publication-title: J Gen Intern Med doi: 10.1007/s11606-014-2892-z – volume: 22 start-page: 925 issue: 8 year: 2019 ident: 493_CR32 publication-title: Value Health doi: 10.1016/j.jval.2019.03.010 – volume: 126 start-page: 531 issue: 3 year: 2020 ident: 493_CR54 publication-title: Cancer doi: 10.1002/cncr.32555 – volume: 13 start-page: 7 issue: 1 year: 2020 ident: 493_CR6 publication-title: Patient doi: 10.1007/s40271-019-00400-y – volume: 32 start-page: 393 issue: 6 year: 2016 ident: 493_CR9 publication-title: Int J Technol Assess Health Care doi: 10.1017/S0266462316000568 – ident: 493_CR33 – ident: 493_CR46 doi: 10.1111/dmcn.13277 – ident: 493_CR53 – volume: 28 start-page: 399 issue: 2 year: 2019 ident: 493_CR47 publication-title: Qual Life Res doi: 10.1007/s11136-018-2025-y – volume: 61 start-page: 75 issue: 1 year: 2018 ident: 493_CR58 publication-title: Dev Med Child Neurol doi: 10.1111/dmcn.13977 – volume: 7 start-page: 323 year: 1998 ident: 493_CR27 publication-title: Qual Life Res doi: 10.1023/A:1008846618880 – volume: 20 start-page: 1 issue: 1 year: 2019 ident: 493_CR37 publication-title: Respir Res doi: 10.1186/s12931-019-1010-5 – volume: 14 start-page: 1 issue: 1 year: 2019 ident: 493_CR35 publication-title: Orphanet J Rare Dis doi: 10.1186/s13023-019-1254-7 – volume: 13 start-page: 1726 issue: 10 year: 2016 ident: 493_CR57 publication-title: Ann Am Thorac Soc doi: 10.1513/AnnalsATS.201603-198OC – ident: 493_CR22 – volume: 4 start-page: 53 year: 2014 ident: 493_CR11 publication-title: Value Health Reg issues doi: 10.1016/j.vhri.2014.06.003 – volume: 13 start-page: 795 year: 2019 ident: 493_CR25 publication-title: Patient Prefer Adhere doi: 10.2147/PPA.S201632 – volume: 4 start-page: 10 year: 2018 ident: 493_CR44 publication-title: Res Invol Engag doi: 10.1186/s40900-018-0093-3 – year: 2019 ident: 493_CR17 publication-title: Orphanet J Rare Dis doi: 10.1186/s13023-019-1004-x – volume: 14 start-page: 1 issue: 1 year: 2019 ident: 493_CR49 publication-title: Orphanet J. Rare Dis. doi: 10.1186/s13023-019-1108-3 – volume: 43 start-page: 1810 issue: 12 year: 2007 ident: 493_CR29 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2007.05.029 – year: 2019 ident: 493_CR19 publication-title: Osteoporos Int doi: 10.1007/s00198-018-4690-7 – volume: 3 start-page: 1 issue: 1 year: 2019 ident: 493_CR38 publication-title: J. Patient-Rep Outcomes doi: 10.1186/s41687-019-0099-0 – volume: 3 start-page: 439 issue: 2 year: 2018 ident: 493_CR55 publication-title: Kidney Int Rep doi: 10.1016/j.ekir.2017.11.016 – ident: 493_CR34 – year: 2017 ident: 493_CR13 publication-title: Value Health. doi: 10.1016/j.jval.2017.05.015 – volume: 8 start-page: 94 issue: 2 year: 2005 ident: 493_CR30 publication-title: Value Health doi: 10.1111/j.1524-4733.2005.04054.x – year: 2018 ident: 493_CR15 publication-title: Orphanet J Rare Dis doi: 10.1186/s13023-018-0810-x – year: 2018 ident: 493_CR18 publication-title: Orphanet J Rare Dis doi: 10.1186/s13023-018-0958-4 – volume: 15 start-page: 1 year: 2020 ident: 493_CR60 publication-title: Orphanet J Rare Dis. doi: 10.1186/s13023-020-01400-0 – ident: 493_CR21 – volume: 79 start-page: 10 year: 2016 ident: 493_CR36 publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2016.06.010 – ident: 493_CR45 – volume: 28 start-page: 165 issue: 2 year: 2020 ident: 493_CR52 publication-title: Eur J Hum Genet doi: 10.1038/s41431-019-0508-0 – volume: 11 start-page: 1 issue: 1 year: 2016 ident: 493_CR56 publication-title: Orphanet J Rare Dis doi: 10.1186/s13023-016-0444-9 – volume: 44 start-page: 1 year: 2014 ident: 493_CR2 publication-title: York Health Econ Consort. – volume: 169 start-page: 467 issue: 7 year: 2018 ident: 493_CR20 publication-title: Ann Intern Med doi: 10.7326/M18-0850 – volume: 32 start-page: 126 issue: 3 year: 2016 ident: 493_CR31 publication-title: Int J Technol Assess Health Care doi: 10.1017/S0266462316000271 – volume: 35 start-page: 33 issue: s1 year: 2017 ident: 493_CR51 publication-title: Pharmacoeconomics doi: 10.1007/s40273-017-0546-9 – volume: 21 start-page: 651 issue: 4 year: 2012 ident: 493_CR40 publication-title: Qual Life Res doi: 10.1007/s11136-011-9960-1 – ident: 493_CR5 – volume: 11 start-page: 1 issue: 1 year: 2016 ident: 493_CR26 publication-title: Orphanet J Rare Dis doi: 10.1186/s13023-016-0528-6 – ident: 493_CR1 – ident: 493_CR10 – ident: 493_CR28 – volume: 15 start-page: 1 issue: 1 year: 2015 ident: 493_CR24 publication-title: BMC Med Res Methodol doi: 10.1186/s12874-015-0071-5 – volume: 54 start-page: 2011 issue: 12 year: 2019 ident: 493_CR48 publication-title: Pediatr Pulmonol doi: 10.1002/ppul.24507 – year: 2019 ident: 493_CR3 publication-title: J Patient-Rep Outcomes doi: 10.1186/s41687-019-0123-4 – year: 2018 ident: 493_CR14 publication-title: Orphanet J Rare Dis doi: 10.1186/s13023-018-0953-9 – ident: 493_CR41 – volume: 15 start-page: 447 issue: 2 year: 2013 ident: 493_CR8 publication-title: AAPS J doi: 10.1208/s12248-013-9452-z |
| SSID | ssj0061666 |
| Score | 2.4646106 |
| SecondaryResourceType | review_article |
| Snippet | Background
Patient-reported outcome measures (PROMs) are used in health technology assessment (HTA) to measure patient experiences with disease and treatment,... Patient-reported outcome measures (PROMs) are used in health technology assessment (HTA) to measure patient experiences with disease and treatment, allowing a... Background Patient-reported outcome measures (PROMs) are used in health technology assessment (HTA) to measure patient experiences with disease and treatment,... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 485 |
| SubjectTerms | Data collection Disease Health Administration Health Economics Health technology assessment Humans Medicine Medicine & Public Health Patient Reported Outcome Measures Patients Pharmacoeconomics and Health Outcomes Preferences Psychometrics Public Health Quality of Life Quality of Life Research Quantitative psychology Questionnaires Rare diseases Rare Diseases - therapy Review Review Article Technology Assessment, Biomedical |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED9BOyFe-BgMAgMZaW8Q0SSuXT-hAauYtHXVtEl7i1x_aJVQUpqW_fucP5KuTOyFZ5_jWHf23fnufgdwYNFLRq9hmGYziw5KMczwzBl0VujMZWEwlkvfteSETyajqysxjQ9uTUyrbO9Ef1HrWrk38s-omp1_zKn4sviVuq5RLroaW2g8hL5DKqM96H89mkzP27uYuaBYaK-Cy7NhEctmfPEcek4cXencVVZTUaQ326rpjr15N23yr9ipV0njp_-7mWfwJBqj5DBIz3N4YKpdeHQaw-0voEYhIpeNIbUl0wDAmgaL3Whytl7hYoachlfGhswrci6XhnwPMZ-GyEqT41sZ6wQNZBLqnsjmSZ8cduCgL-FyfHTx7UcaOzSkinK6SulIKqfx8hkdajQdCuG6FytmGJOMcS0N2oc0t1lmBapFKbUZKSOQwnpc_GIPelVdmddADPpG3GZUZZmmVGghlbZoK1lV5AOkTyBrmVOqCF_uumj8LDvgZc_QEhlaeoaWNwl87OYsAnjHvdT7LbPKeJCbcsOpBD50w3gEXVxFVqZeIw3lYkBxnzyBV0FEuuWKgrIcpyfAt4SnI3Dw3tsj1fzaw3yjbcz5AL_5qRWzzW_9exdv7t_FW3icu6wcnyW3D73Vcm3ewY76vZo3y_fx-PwBIK0geA priority: 102 providerName: ProQuest |
| Title | The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment |
| URI | https://link.springer.com/article/10.1007/s40271-020-00493-w https://www.ncbi.nlm.nih.gov/pubmed/33462774 https://www.proquest.com/docview/2561987749 https://www.proquest.com/docview/2479043427 https://pubmed.ncbi.nlm.nih.gov/PMC8357707 |
| Volume | 14 |
| WOSCitedRecordID | wos000608643800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1178-1661 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0061666 issn: 1178-1653 databaseCode: M0R dateStart: 20080101 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & allied health premium. customDbUrl: eissn: 1178-1661 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0061666 issn: 1178-1653 databaseCode: 7RV dateStart: 20080101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1178-1661 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0061666 issn: 1178-1653 databaseCode: BENPR dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health & Medical Collection customDbUrl: eissn: 1178-1661 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0061666 issn: 1178-1653 databaseCode: 7X7 dateStart: 20080101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1178-1661 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0061666 issn: 1178-1653 databaseCode: 8C1 dateStart: 20080101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLink customDbUrl: eissn: 1178-1661 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061666 issn: 1178-1653 databaseCode: RSV dateStart: 20080101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1da9sw8FjbMQpla7t2c79QYW-tIbIVyXrsJys0WcjWkjejyBILDGfEyfr3e5Jsd1m3wfYiMDpLlnynu9N9AXywqCWj1tCN6diigpJ2KdKcQWWFjZ0XBueJ8lVLbkW_n41GclAHhVWNt3tjkvQndRvshpqOQNU3cZHQTKbxwwqsIbvLHDkOP9835y93hrBQUgWn5N20DpX5_RjL7OiZjPncVfIXe6lnQ9dv_m8Bm_C6FjvJWcCTLXhhym141asN69uwEa7vSIhKegtTRB9yVxkytWQQUq_GQVY3Bfm0mOOMhvTC_WJFJiUZqpkhl8HaUxFVFuTmJ191gqJxPTZ5uswnZ21a0B24u776cvExrmszxJoJNo9ZprTjdcmYdQsUGlLp6hZrbjhXnItCGZQMWWIptRIZolKFybSRCGF9Rvx0F1bLaWneAzGoFQlLmaa0YEwWUunCopRkdZp0ED4C2vyiXNeJy139jG95m3LZ72yOO5v7nc0fIjhp3_ke0nb8Ffqg-fN5TcJVjrKgu5ARTEZw3HYj8TmLiirNdIEwTMgOw3WKCN4FRGmnS1PGE3w9ArGEQi2AS-y93FNOvvoE3ygVC9HBMU8bRHr6rD-vYu_fwPdhPXH-Od5f7gBW57OFOYSX-sd8Us2OYEUM7107Er7NsM0u6BGsnV_1B0N86nVci4T3CE3iIMA |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD4aAwEv3GGBAUaCJxbROK5dPyA0MaZVa8s0bWhvwbUdUQklW9NS7U_tN3JsJyllYm974Dknl5N8Pj5fzg3gbY4sGVlDN07GORKUtJvgmrNIVtjYZWFwTpWfWjIQo1Hv5EQerMFFUwvj0iobm-gNtSm1-0f-Abdmx48Fk59Oz2I3NcpFV5sRGgEW-_Z8gZSt-tjfwe_7jtLdL0ef9-J6qkCsmWCzmPWUdlaajlnX4HaXSjdxV3PLueJcGGXRp2E0T5JcoilXytiethIlct_LPcXr3oCbaMcTl0ImDr81lp-7EFwY5oLK8m5aF-n4Uj3kaQKJO3V13Eym8WJ1I7zk3V5O0vwrUus3wN37_9urewD3alebbIe18RDWbPEIbg_rZILHUOISIceVJWVODkJ72TjwEWvI1_kMlbNkGP6hVmRSkEM1tWQnRLQqogpD-n_k4xN0_0mo6iLLgAXZblufPoHja1H3KawXZWE3gFhkfiJPmE4Sw5g0UmmToyeY65R2UD6CpAFDpuvm7G5GyM-sbSvtAZQhgDIPoGwRwfv2nNPQmuRK6c0GHFltpqpsiYwI3rSH0cC4qJEqbDlHGSZkh6GeIoJnAZLt7dKUcYqnRyBWwNoKuOblq0eKyQ_fxBw9fyE6eM2tBtbLx_q3Fs-v1uI13Nk7Gg6yQX-0_wLuUpd_5PMBN2F9Np3bl3BL_5pNqukrv3AJfL9uuP8GLUR5sw |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VgiouvB-mBRYJTmA1tje72QOqqoaIqG2IEJV6czf7EJGQXeKEiL_Gr-vsru00VPTWA2ePnUzy7ex-nm9mAN5aZMnIGrpxMrFIULJugmvOIFmhE6fCYCyVfmrJER-NeqenYrwBf5paGCerbGKiD9S6VO4d-S5uzY4fcyp2bS2LGPcHe-c_YzdBymVam3EaASKH5vcS6Vv1cdjH__pdmg4-fTv4HNcTBmJFOZ3HtCeVi9jphHY1bn2ZcNN3FTOMSca4lgbPNzS1SWIFhnUptekpI9DC-r7uGT73FtzmGaLYVakftPIS5tJxYbALOs66WV2w48v2kLNxJPGpq-mmIouX65vilZPuVcHmX1lbvxkO7v_PP-MDuFcfwcl-WDMPYcMUj2DruBYZPIYSlw45qQwpLRmHtrNx4ClGky-LOTpqyHF4t1qRaUG-ypkh_ZDpqogsNBle0ukTpAUkVHuRVSKD7LctUZ_AyY24-xQ2i7Iwz4EYZITcJlQliaZUaCGVtnhCtCpLO2gfQdIAI1d103Y3O-RH3rab9mDKEUy5B1O-jOB9e895aFlyrfVOA5S8Dl9VvkJJBG_ayxh4XDZJFqZcoA3lokPRTx7BswDP9uOyjLIUb4-ArwG3NXBNzdevFNPvvrk5MgLOO_jMDw3EV1_r3168uN6L17CFKM-PhqPDbbibOlmSlwnuwOZ8tjAv4Y76NZ9Ws1d-DRM4u2m0XwCzAYIO |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Use+of+Patient-Reported+Outcome+Measures+in+Rare+Diseases+and+Implications+for+Health+Technology+Assessment&rft.jtitle=The+patient+%3A+patient-centered+outcomes+research&rft.au=Whittal%2C+Amanda&rft.au=Meregaglia%2C+Michela&rft.au=Nicod%2C+Elena&rft.date=2021-09-01&rft.pub=Springer+International+Publishing&rft.issn=1178-1653&rft.eissn=1178-1661&rft.volume=14&rft.issue=5&rft.spage=485&rft.epage=503&rft_id=info:doi/10.1007%2Fs40271-020-00493-w&rft.externalDocID=10_1007_s40271_020_00493_w |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1178-1653&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1178-1653&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1178-1653&client=summon |